<DOC>
	<DOCNO>NCT02994602</DOCNO>
	<brief_summary>This two-center , open-label study conduct healthy male female volunteer two academic research center . The study consist three single application Nestorone ( NES ) + testosterone ( T ) combine gel shoulders/upper arm male participant follow 2 hour later supervise skin contact non-dosed female participant application site day 1 , 8 , 15 . Effect Washing Clothing Barrier Application assess .</brief_summary>
	<brief_title>Study Serum Testosterone Nestorone Females After Secondary Exposure Nestorone ® ( NES ) + Testosterone ( T ) Combined Gel Applied Shoulders Upper Arms Males</brief_title>
	<detailed_description>This two-center , open-label study conduct healthy male female volunteer two academic research center . The study consist three single application Nestorone ( NES ) + testosterone ( T ) combine gel shoulders/upper arm male participant follow 2 hour later supervise skin contact non-dosed female participant application site day 1 , 8 , 15 . On day 1 , male participant wear 100 % cotton T-shirt application area skin contact female . On day 8 , male participant shower approximately 1 hour 45 minute gel application engage skin contact female participant ( 2 hour gel application ) wash area soap water dry . A measurement residual Nestorone testosterone take male 's skin single location application site use adhesive D-square strip 90 minute application ( 30 minute shower/90 minute gel application ) 30 minute shower rub ( 150 minute application ) . On day 15 , shower clothe barrier male participant skin contact female participant . A measurement residual Nestorone testosterone take single location application use adhesive D-square strip site 90 minute 150 minute application . An end study/exit visit occur male female participant two week treatment completion .</detailed_description>
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Male participant Inclusion Criteria Men meet follow criterion eligible enrollment trial : 1 . Good health confirm medical history , physical examination , clinical laboratory test blood urine time screening ; 2 . 18 50 year age ; 3 . BMI ≥ 18 &lt; 35 kg/m2 ; 4 . No history androgen use prior first screen visit follow : 1 . 1 month prior oral transdermal androgen , 2 . 3 month prior Testosterone cypionate enanthate injection , 3 . 6 month prior Testosterone undecanoate injection ; 5 . Agreement use recognize effective method short act contraception partner ( i.e . minimum use doublebarrier method condom spermicide ) entire study ; 6 . In opinion investigator , male subject willing able comply protocol ; 7 . Provision valid , write informed consent . Female participant Inclusion Criteria Women meet follow criterion eligible enrollment trial : 1 . Good general health ( BMI ≥18 &lt; 30 kg/m2 ) chronic medical condition result periodic exacerbation require significant medical care ; 2 . Aged 18 40 year , enrollment visit ; 3 . Not pregnant breastfeeding . 4 . Agreement use recognize effective method contraception throughout study 5 . Willingness ability provide valid , write informed consent comply protocol ; 6 . No desire pregnancy within next 6 month . Exclusion Male participant Exclusion Criteria Men meet follow criterion eligible enrollment trial : 1 . Men participate another clinical trial involve investigational drug within last 30 day prior first screen visit . 2 . Men live catchment area study site within reasonable travel time site . 3 . Any clinically significant abnormal finding screen per Investigator 's medical judgement . 4 . Elevated PSA ( e.g . level ≥ 4 ng/mL ) , accord study site 's local laboratory reference normal value adult men . 5 . Abnormal serum chemistry value may indicate clinically significant liver kidney dysfunction . Other abnormal laboratory value may also exclusionary , consider investigator clinically significant . 6 . Use androgens anabolic steroid may affect testosterone measurement 7 . Diastolic blood pressure ( DBP ) ≥ 85 Systolic blood pressure ( SBP ) ≥ 135 mm Hg ; ( BP take three time approximately 5 minute interval mean 3 measurement consider ) . 8 . History hypertension ( wellcontrolled treat hypertension ( &lt; 135/85 ) allow ) . 9 . Known history primary testicular disease disorder hypothalamicpituitary axis . 10 . Known hypersensitivity progestins testosterone . 11 . History prostate breast carcinoma 12 . Significant low urinary obstructive symptom ( IPSS &gt; 19 ) . 13 . Known history significant cardiac , renal , hepatic prostatic disease . 14 . History thromboembolic disease . 15 . A serious systemic disease diabetes mellitus ( include diabetes control treatment ) , HIV , morbid obesity . 16 . Current active ongoing Hepatitis infection 17 . Known suspected current alcohol dependence syndrome , chronic marijuana use , illicit drug use may affect metabolism/transformation steroid hormone study treatment compliance . 18 . Known active chronic dermatitis severe skin disorder . 19 . Desiring fertility within 6 month study participation . 20 . History severe depression serious mental health disorder . 21 . Men participate competitive sport drug screening prohibit substance ( include anabolic steroid ) routine advise relative temporary hazard participate study may sport status . Female participant Exclusion Criteria Women meet follow criterion eligible enrollment trial : 1 . Desire become pregnant study . 2 . Breastfeeding 3 . Known suspected current alcoholism drug abuse . 4 . History thrombosis 5 . Serum testosterone outside normal reference range local laboratory standard evidence hirsutism ( modify FerrimanGalwey score &gt; 8 ) 6 . Participation another clinical trial involve investigational drug within last 30 day prior first screen visit . 7 . Current pregnancy . 8 . Known hypersensitivity progestins testosterone . 9 . Any clinically significant abnormal finding screen per Investigator 's medical judgement . 10 . Use androgens anabolic steroid may affect testosterone measurement . 11 . Known active chronic dermatitis severe skin disorder . 12 . Known suspected current alcohol dependence syndrome , chronic marijuana use , illicit drug use may affect metabolism/transformation steroid hormone study treatment compliance . 13 . Not live catchment area study site within reasonable travel time site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy Men</keyword>
	<keyword>Male Contraception</keyword>
	<keyword>Healthy Women</keyword>
	<keyword>Transfer</keyword>
	<keyword>Transference</keyword>
	<keyword>Gel</keyword>
	<keyword>Nestorone</keyword>
	<keyword>Testosterone</keyword>
</DOC>